Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 196.12
NLNK's Cash to Debt is ranked higher than
52% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. NLNK: 196.12 )
Ranked among companies with meaningful Cash to Debt only.
NLNK' s 10-Year Cash to Debt Range
Min: 0.79  Med: 42.92 Max: N/A
Current: 196.12
Equity to Asset 0.93
NLNK's Equity to Asset is ranked higher than
90% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NLNK: 0.93 )
Ranked among companies with meaningful Equity to Asset only.
NLNK' s 10-Year Equity to Asset Range
Min: -5.11  Med: 0.77 Max: 0.93
Current: 0.93
-5.11
0.93
Interest Coverage 4522.04
NLNK's Interest Coverage is ranked lower than
80% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NLNK: 4522.04 )
Ranked among companies with meaningful Interest Coverage only.
NLNK' s 10-Year Interest Coverage Range
Min: 4522.04  Med: 4522.04 Max: 4522.04
Current: 4522.04
F-Score: 6
Z-Score: 50.14
WACC vs ROIC
7.79%
821.81%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 60.78
NLNK's Operating margin (%) is ranked higher than
97% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -71.95 vs. NLNK: 60.78 )
Ranked among companies with meaningful Operating margin (%) only.
NLNK' s 10-Year Operating margin (%) Range
Min: -2849.13  Med: -1108.03 Max: 68.12
Current: 60.78
-2849.13
68.12
Net-margin (%) 54.12
NLNK's Net-margin (%) is ranked higher than
97% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -68.66 vs. NLNK: 54.12 )
Ranked among companies with meaningful Net-margin (%) only.
NLNK' s 10-Year Net-margin (%) Range
Min: -2852.7  Med: -1067.88 Max: 59.6
Current: 54.12
-2852.7
59.6
ROE (%) 73.48
NLNK's ROE (%) is ranked higher than
98% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. NLNK: 73.48 )
Ranked among companies with meaningful ROE (%) only.
NLNK' s 10-Year ROE (%) Range
Min: -85.27  Med: -81.78 Max: 78.49
Current: 73.48
-85.27
78.49
ROA (%) 64.96
NLNK's ROA (%) is ranked higher than
99% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. NLNK: 64.96 )
Ranked among companies with meaningful ROA (%) only.
NLNK' s 10-Year ROA (%) Range
Min: -75.86  Med: -59.98 Max: 66.66
Current: 64.96
-75.86
66.66
ROC (Joel Greenblatt) (%) 619.16
NLNK's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. NLNK: 619.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NLNK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -709.08  Med: -369.45 Max: 799.97
Current: 619.16
-709.08
799.97
Revenue Growth (3Y)(%) 161.80
NLNK's Revenue Growth (3Y)(%) is ranked higher than
98% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. NLNK: 161.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NLNK' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 0.00 Max: 161.8
Current: 161.8
0
161.8
» NLNK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

NLNK Guru Trades in Q4 2014

First Eagle Investment 1,406,386 sh (+11.83%)
First Eagle Investment 1,406,386 sh (+11.83%)
First Eagle Investment 12,375 sh (unchged)
Stanley Druckenmiller Sold Out
» More
Q1 2015

NLNK Guru Trades in Q1 2015

Joel Greenblatt 838,221 sh (New)
Paul Tudor Jones 5,380 sh (New)
First Eagle Investment 1,430,700 sh (+1.73%)
First Eagle Investment 10,959 sh (unchged)
» More
Q2 2015

NLNK Guru Trades in Q2 2015

Joel Greenblatt 1,244,856 sh (+48.51%)
First Eagle Investment 1,719,600 sh (+20.19%)
Paul Tudor Jones 5,700 sh (+5.95%)
First Eagle Investment 7,597 sh (unchged)
» More
2015

NLNK Guru Trades in 2015

First Eagle Investment 1,683,800 sh (-2.08%)
» More
» Details

Insider Trades

Latest Guru Trades with NLNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 17.21
NLNK's P/E(ttm) is ranked higher than
78% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 36.10 vs. NLNK: 17.21 )
Ranked among companies with meaningful P/E(ttm) only.
NLNK' s 10-Year P/E(ttm) Range
Min: 13.51  Med: 17.21 Max: 19.58
Current: 17.21
13.51
19.58
Forward P/E 15.17
NLNK's Forward P/E is ranked higher than
77% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 22.73 vs. NLNK: 15.17 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 17.00
NLNK's PE(NRI) is ranked higher than
79% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 35.00 vs. NLNK: 17.00 )
Ranked among companies with meaningful PE(NRI) only.
NLNK' s 10-Year PE(NRI) Range
Min: 13.5  Med: 17.20 Max: 19.56
Current: 17
13.5
19.56
P/B 6.01
NLNK's P/B is ranked lower than
63% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. NLNK: 6.01 )
Ranked among companies with meaningful P/B only.
NLNK' s 10-Year P/B Range
Min: 3.6  Med: 8.53 Max: 21.14
Current: 6.01
3.6
21.14
P/S 6.85
NLNK's P/S is ranked higher than
57% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.19 vs. NLNK: 6.85 )
Ranked among companies with meaningful P/S only.
NLNK' s 10-Year P/S Range
Min: 6.66  Med: 230.00 Max: 1162.5
Current: 6.85
6.66
1162.5
PFCF 19.23
NLNK's PFCF is ranked higher than
77% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 39.55 vs. NLNK: 19.23 )
Ranked among companies with meaningful PFCF only.
NLNK' s 10-Year PFCF Range
Min: 13.65  Med: 18.17 Max: 22.15
Current: 19.23
13.65
22.15
POCF 18.22
NLNK's POCF is ranked higher than
72% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. NLNK: 18.22 )
Ranked among companies with meaningful POCF only.
NLNK' s 10-Year POCF Range
Min: 13.32  Med: 17.50 Max: 21.38
Current: 18.22
13.32
21.38
EV-to-EBIT 8.84
NLNK's EV-to-EBIT is ranked higher than
85% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 27.86 vs. NLNK: 8.84 )
Ranked among companies with meaningful EV-to-EBIT only.
NLNK' s 10-Year EV-to-EBIT Range
Min: -36.7  Med: -11.70 Max: 13.5
Current: 8.84
-36.7
13.5
Current Ratio 25.95
NLNK's Current Ratio is ranked higher than
94% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. NLNK: 25.95 )
Ranked among companies with meaningful Current Ratio only.
NLNK' s 10-Year Current Ratio Range
Min: 0.97  Med: 10.74 Max: 25.95
Current: 25.95
0.97
25.95
Quick Ratio 25.95
NLNK's Quick Ratio is ranked higher than
94% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. NLNK: 25.95 )
Ranked among companies with meaningful Quick Ratio only.
NLNK' s 10-Year Quick Ratio Range
Min: 0.97  Med: 10.74 Max: 25.95
Current: 25.95
0.97
25.95
Days Sales Outstanding 25.92
NLNK's Days Sales Outstanding is ranked higher than
80% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. NLNK: 25.92 )
Ranked among companies with meaningful Days Sales Outstanding only.
NLNK' s 10-Year Days Sales Outstanding Range
Min: 40.89  Med: 159.67 Max: 617.06
Current: 25.92
40.89
617.06

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.36
NLNK's Price/Net Cash is ranked higher than
52% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 7.71 vs. NLNK: 7.36 )
Ranked among companies with meaningful Price/Net Cash only.
NLNK' s 10-Year Price/Net Cash Range
Min: 5.21  Med: 11.01 Max: 29.76
Current: 7.36
5.21
29.76
Price/Net Current Asset Value 6.31
NLNK's Price/Net Current Asset Value is ranked higher than
53% of the 537 Companies
in the Global Biotechnology industry.

( Industry Median: 6.85 vs. NLNK: 6.31 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NLNK' s 10-Year Price/Net Current Asset Value Range
Min: 4.66  Med: 10.49 Max: 21.93
Current: 6.31
4.66
21.93
Price/Tangible Book 6.06
NLNK's Price/Tangible Book is ranked lower than
54% of the 693 Companies
in the Global Biotechnology industry.

( Industry Median: 5.31 vs. NLNK: 6.06 )
Ranked among companies with meaningful Price/Tangible Book only.
NLNK' s 10-Year Price/Tangible Book Range
Min: 3.93  Med: 9.30 Max: 14.71
Current: 6.06
3.93
14.71
Price/Median PS Value 0.04
NLNK's Price/Median PS Value is ranked higher than
99% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: 1.08 vs. NLNK: 0.04 )
Ranked among companies with meaningful Price/Median PS Value only.
NLNK' s 10-Year Price/Median PS Value Range
Min: 0.03  Med: 0.93 Max: 3.08
Current: 0.04
0.03
3.08
Price/Graham Number 1.77
NLNK's Price/Graham Number is ranked higher than
73% of the 169 Companies
in the Global Biotechnology industry.

( Industry Median: 3.18 vs. NLNK: 1.77 )
Ranked among companies with meaningful Price/Graham Number only.
NLNK' s 10-Year Price/Graham Number Range
Min: 1.62  Med: 1.64 Max: 1.94
Current: 1.77
1.62
1.94
Earnings Yield (Greenblatt) (%) 11.29
NLNK's Earnings Yield (Greenblatt) (%) is ranked higher than
96% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. NLNK: 11.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NLNK' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 7.4  Med: 9.70 Max: 13.1
Current: 11.29
7.4
13.1

Analyst Estimate

Dec15 Dec16
EPS($) -1.46 -2.80
EPS without NRI($) -1.46 -2.80

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:4NX.Germany,
NewLink Genetics Corp., was incorporated in Delaware on June 4, 1999. The Company is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its products include biologic and small-molecule immunotherapy product candidates intended to treat oncology indications. Its product candidate, HyperAcute Pancreas cancer immunotherapy, or HyperAcute Pancreas, is being studied in a Phase 3 clinical trial in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment, or SPA, with the United States Food and Drug Administration, or FDA. The Company initiated this trial based on encouraging interim Phase 2 data that suggests improvement in both disease-free and overall survival. The Company has also received Fast Track and Orphan Drug designations from the FDA for this product candidate for the adjuvant treatment of surgically-resected pancreatic cancer. It has three additional product candidates in clinical development, including its HyperAcute Lung cancer immunotherapy, or HyperAcute Lung, which is being studied in a Phase 1/2 clinical trial at the National Cancer Institute, or NCI, and its HyperAcute Melanoma cancer immunotherapy, or HyperAcute Melanoma, which is being studied in an investigator-initiated Phase 2 clinical trial. To date, its HyperAcute product candidates have been dosed in more than 200 cancer patients either as a monotherapy or in combination with other therapies and have demonstrated a favorable safety profile. Its HyperAcute product candidates are based on its proprietary HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. Its HyperAcute product candidates use allogeneic (non-patient specific) cells from previously established cell lines rather than cells derived from the patient. The Company thinks its approach enables a simpler, consistent and scalable manufacturing process than therapies based on patient specific tissues or cells. Its strategy is to discover, develop and commercialize immunotherapeutic products for the treatment of cancer where the needs of patients are unmet by current therapies. The Company faces competition from other public and private biopharmaceutical companies, public and private universities and research organizations actively engaged in the discovery and research and development of products for cancer. The Company is subject to federal, state, local and foreign regulation.
» More Articles for NLNK

Headlines

Articles On GuruFocus.com
These Companies Show High Profit and Low Debt Jun 17 2015 
When A Stock Doubles, Don’t Trim It Automatically May 27 2015 
Greenblatt's Top Buys During First Quarter May 22 2015 
NewLink Genetics Corporation Offers a Risky Way to Generate Income Sep 11 2013 
Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse I Jun 30 2012 

More From Other Websites
NewLink Genetics Corp. Earnings Q2, 2015 Aug 27 2015
From Cancer To Ebola, NewLink Genetics Seeks Vaccines Aug 21 2015
NEWLINK GENETICS CORP Financials Aug 18 2015
NewLink Genetics Corp.: Price momentum supported by strong fundamentals Aug 18 2015
NEWLINK GENETICS CORP Files SEC form 10-Q, Quarterly Report Aug 06 2015
Only two Ebola cases reported in past week, but risks remain - WHO Aug 04 2015
Positive Developments Around Ebola Aug 03 2015
There's more to Merck's Ebola vaccine than money Jul 31 2015
Merck: Study shows potential Ebola vaccine has '100 percent efficacy' Jul 31 2015
Stocks Open Mixed, Dow Lags; Expedia, Amgen, NewLink Rising Jul 31 2015
CNBC update: Ebola vaccine Jul 31 2015
NEWLINK GENETICS CORP Files SEC form 8-K, Other Events Jul 31 2015
Vaccine Candidate Potentially Effective Against Ebola in Large Trial in Guinea Jul 31 2015
Q2 2015 NewLink Genetics Corp Earnings Release - Time Not Supplied Jul 31 2015
NewLink reports 2Q loss Jul 31 2015
NewLink reports 2Q loss Jul 31 2015
NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial... Jul 31 2015
NewLink Genetics to Host Its Second Quarter 2015 Earnings Conference Call on July 31, 2015 Jul 24 2015
NewLink Genetics Announces That Dr. Thomas Monath Received Award From American Veterinary... Jul 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK